Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate penetrates abnormal skin cells and is converted intracellularly into protoporphyrin IX, a photosensitizer. When the area is exposed to a specific wavelength of visible light, protoporphyrin IX produces reactive oxygen species that selectively destroy dysplastic keratinocytes while sparing normal tissue.

The prescribed amount of Metvix is determined by the treating physician based on lesion size, location, and clinical judgment. The healthcare professional will decide the exact quantity of cream to apply and the illumination protocol for each patient.

Safety data for methyl aminolevulinate in pregnancy or lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metvix offers a photodynamic therapy approach, which can treat multiple lesions in a single field and may provide better cosmetic outcomes compared with lesion‑destructive methods such as cryotherapy or topical 5‑fluorouracil. The choice depends on lesion characteristics, patient preference, and clinician experience.

Metvix should be stored at room temperature below 25 °C, in its original container, protected from moisture and direct light. Keep the product out of reach of children and avoid freezing the cream.

A thin layer of Metvix cream is applied to the cleaned, pre‑treated skin area by a healthcare professional. After a defined incubation period, the area is illuminated with a calibrated light source for a specific duration, completing the photodynamic therapy session.

Serious risks include severe photosensitivity reactions, secondary skin infection, allergic contact dermatitis, and rare ocular injury if proper eye protection is not used during illumination. Patients should be monitored closely for any unexpected adverse events.

Metvix is contraindicated in patients with known hypersensitivity to methyl aminolevulinate or any cream excipients, in individuals with active skin infections at the treatment site, and in those who cannot avoid light exposure during the required post‑treatment period.